Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily Dialogue, 7/27/11, Washington is taking its toll

The 6 W’s: Who, what, where, when, why and what of it…

US stock market futures kept in a tight range Wednesday amid a flood of earnings announcements.  

US stocks began lower on Wednesday as the political stalemate over the nation’s debt limit continued, and after the government reported orders for durable goods fell in June. The Dow declined 66 points to 12,435.30. The Standard & Poor’s 500 Index shed 8.79 points to 1,323.15. The NASDAQ fell 21.54 points to 2,818.42.

It’s been a hot summer, and it’s been even hotter in Washington, where Democrats and Republicans have been burning down the House with a pitched battle over the debt ceiling, the cap that Congress puts on the national debt.  I still think a debt deal will be made … who wants to be the one known for … kissing the AAA rating of the US … GOODBYE …

 

Regenerative medicine/stem cell universe is “buoyant, not sinking … just floating” on 7/271/11 …  The NASDAQ is DOWN -70.76 (-1.89%) to 2,769.20. The Dow is DOWN -175.48 (-0.97%) to 12,379.52.

 

Who is UP … Advanced Cell Technology (ACTC.OB), International Stem cell (OTCQB:ISCO) are up …

 

What’s driving the regenerative medicine/stem cell market …

 

Judge Dismisses Suit on Federal Stem Cell Research: Judge Royce Lamberth, chief of the federal court in Washington is throwing out a lawsuit challenging the Obama administration’s funding of embryonic stem cell research. The lawsuit claimed the research violated a 1996 law that prohibits taxpayer financing for work that harms an embryo. But the Obama administration policy allows research on embryos that were culled long ago through private funding. US District Judge Royce Lamberth, last year said the lawsuit was likely to succeed and he issued an injunction to block the research while the case continued. But the appeals court overturned his injunction and said the case was likely to fail. The Bottom Line: Lamberth said in his ruling Wednesday that he was bound by the higher court’s analysis and ruled in favor of the administration’s motion to dismiss the case.

Bioheart Announces Publication by the American Heart Journal: OTCBB: BHRT’s clinical paper has been accepted for publication in a prominent peer reviewed medical journal. The American Heart Journal has accepted for publication “A Double-blind, Randomized, Controlled, Multicenter Study to Assess the Safety and Cardiovascular Effects of Skeletal Myoblast Implantation by Catheter Delivery in Patients with Chronic Heart Failure Following Myocardial Infarction.” Results of part one of the MARVEL P2/3 study were previously presented by Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University. The bottom line, in comparison with the placebo group, myoblast therapy was associated with sustained (6 months) improvements in exercise capacity distance of greater than 90 meters, an increase that would be of great importance to patients if replicated in larger studies.

Marshall Edwards, Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cell: MSHL published of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. NV-128 is an investigational compound and lead mitochondrial inhibitor drug candidate, NV-344. The bottom line, a major obstacle in the successful treatment of ovarian cancer is disease recurrence due in part to the outgrowth of chemotherapy-resistant ovarian cancer stem cells. This study shows that NV-128 can specifically target the mitochondriain patient-derived ovarian cancer stem cells to induce cell death in an otherwise chemo-resistant cell population. Previous studies conducted at Yale University showed that NV-128 is able to inhibit tumor growth in an ovarian cancer animal model without inducing significant toxicity, suggesting a sufficient therapeutic window that may allow compounds of this class to be safely administered to patients. Once administered, NV-128 is demethylated in vivo to NV-344, its active metabolite, which has been shown to be significantly more potent than NV-128 in pre-clinical research studies.  MSHL plans to complete the required pre-clinical studies of NV-344 to submit an Investigational New Drug (NYSE:IND) application to the US FDA) by Q1/12. . The publication, entitled “Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells,” is available on the Molecular Cancer Therapeutics website and scheduled to print in the August issue of the journal.